

FILED 1/27/12

OK TO ENTER /LAB/



Pillsbury Winthrop Shaw Pittman LLP
 12255 El Camino Real, Suite 300 | San Diego, CA 92130-4088 | tel 619.234.5000 | fax 858.509.4010

FACSIMILE**Total Pages (including cover): 5**

HOUSTON	Date:	January 27, 2012	Must Be Sent By:
LONDON	To:	Examiner Bristol	Fax No: (571) 273-6883
LOS ANGELES	Company:	U.S. Patent and Trademark Office	Phone No: (571) 272-6883
NEW YORK	Confirm:	Confirmed By:	
NORTHERN VIRGINIA	From:	Robert M. Bedgood	Phone No: 858.509.4065
ORANGE COUNTY	User No:	14660	C/M No: 043043-0359295
SACRAMENTO	Comments:		
SAN DIEGO			
SAN DIEGO-NORTH COUNTY			
SAN FRANCISCO			
SHANGHAI			
SILICON VALLEY			
TOKYO			
WASHINGTON DC			

--NOT FOR ENTRY INTO FILE--

Attached please find the Proposed Amended Claims for your review.

Thank you.

Confidentiality Note:

The documents accompanying this facsimile transmission may contain confidential information which is legally privileged. The information is intended only for the use of the individual or entity named above. If you are not the intended recipient, or the person responsible for delivering it to the intended recipient, you are hereby notified that any disclosure, copying, distribution or use of any of the information contained in this transmission is strictly PROHIBITED. If you have received this transmission in error, please immediately notify us by telephone and mail the original transmission to us. Thank you.

If you have not properly received this fax, please call (619) 234-5000. Thank you.

Operator: _____ Time Sent: _____ Batch ID: _____

www.pillsburylaw.com

NOT FOR ENTRY INTO FILE**NOT FOR ENTRY INTO FILE****Proposed Amended Claims**

Application Serial No.: 10/579,290
Attorney Docket: 043043-0359295

Please cancel withdrawn claims 89 to 91 and amend the claims as follows:

Claims 1-72 (Cancelled)

73. (Currently Amended) A purified antibody or functional fragment thereof comprising a light chain (V_L) variable region sequence and a heavy chain (V_H) variable region sequence, wherein said antibody or functional fragment specifically binds to an epitope of an antigen expressed by at least one of BXPC-3 (ATCC Accession No. CRL-1687), 23132/87 (DSMZ Accession No. ACC 201), COLO-206F (DSMZ Accession No. ACC 21), COLO-699 (DSMZ Accession No. ACC 196), or LOU-NH91 (DSMZ Accession No. ACC 393) neoplastic cells and binds to apolipoprotein B containing low density lipoproteins (LDL) and apolipoprotein B containing oxidized LDL (oxLDL), wherein SAM-6 antibody comprising the amino acid sequences of SEQ ID NO:1 and SEQ ID NO:3 specifically binds to said epitope of the antigen expressed by at least one of said neoplastic cells, and wherein said heavy chain variable region sequence has CDR sequences identical to CDR1, CDR2 and CDR3 of SEQ ID NO:3.

74.-79. (Cancelled)

80. (Previously Amended) A purified antibody or functional fragment thereof, comprising SEQ ID NO:1 and SEQ ID NO:3.

81. (Previously Presented) The purified antibody or functional fragment thereof according to Claim 73, wherein said functional fragment comprises SEQ ID NO:1 and SEQ ID NO:3.

82.-105. (Cancelled)

106. (Previously Presented) The purified antibody or functional fragment thereof according to Claim 73, wherein said light chain (V_L) variable region sequence is at least 80% identical to SEQ ID NO:1, and wherein said heavy chain (V_H) variable region sequence is at least 90% identical to SEQ ID NO:3.

107. (Previously Presented) The purified antibody or functional fragment thereof according to Claim 73, comprising the functional fragment thercof.

VOLLMERS ET AL. -- 10/579,290
Attorney Docket: 043043-0359295

108. (Currently Amended) The purified antibody or functional fragment thereof according to Claim 107, wherein said functional fragment thereof is selected from the group consisting of [[V_H,]] F_v, Fab, Fab' and F(ab')₂.

109. (Previously Presented) The purified antibody or functional fragment thereof according to Claim 73, wherein said light chain variable region sequence has CDR sequences identical to CDR1, CDR2 and CDR3 of SEQ ID NO:1.

110. (Cancel)

111. (Previously Amended) The purified antibody or functional fragment thereof according to Claim 73, wherein the complementary-determining region (CDR) of said light chain (V_L) variable region sequence is identical to CDRs [Ser-Gly-Asp-Lys-Leu-Gly-Asp-Lys-Tyr-Ala-Cys (CDR1) and Gln-Asp-Ser-Lys-Arg-Pro-Ser (CDR2) and Gln-Ala-Trp-Asp-Ser-Ser-Ile-Val-Val (CDR3) of SEQ ID NO:1].

112. (Previously Presented) The purified antibody or functional fragment thereof according to Claim 73, wherein said antibody or functional fragment thereof is a monoclonal antibody.

113.-114. (Cancelled)

115. (Previously Presented) The purified antibody or functional fragment thereof according to Claim 73, wherein said antibody or functional fragment thereof inhibits cell proliferation of 23132/87 (DSMZ Accession No. ACC 201) cells.

116. (Previously Presented) The purified antibody or functional fragment thereof according to Claim 73, wherein said antibody or functional fragment thereof induces apoptosis of at least one of BXPC-3 (ATCC Accession No. CRL-1687) and 23132/87 (DSMZ Accession No. ACC 201) cells.

117. -120. (Cancelled)

121. (Previously Presented) The purified antibody or functional fragment thereof according to Claim 73, wherein the antibody or functional fragment thereof is a monomeric or pentameric form.

122. (Currently Amended) A purified polypeptide comprising a heavy chain (V_H) variable region sequence, wherein said heavy chain variable region sequence has CDR sequences identical to CDR1, CDR2 and CDR3 of SEQ ID NO:3, wherein said heavy chain (V_H) variable region sequence specifically binds to an epitope of an antigen expressed by at least

VOLLMERS ET AL. -- 10/579,290
Attorney Docket: 043043-0359295

one of BXPC-3 (ATCC Accession No. CRL-1687), 23132/87 (DSMZ Accession No. ACC 201), COLO-206F (DSMZ Accession No. ACC 21), COLO-699 (DSMZ Accession No. ACC 196), or LOU-NH91 (DSMZ Accession No. ACC 393) neoplastic cells and binds to apolipoprotein B containing low density lipoproteins (LDL) and apolipoprotein B containing oxidized LDL (oxLDL), and wherein SAM-6 antibody comprising the amino acid sequences of SEQ ID NO:1 and SEQ ID NO:3 specifically binds to said epitope of the antigen expressed by at least one of said neoplastic cells.

123. (Previously Presented) The purified polypeptide according to Claim 122, wherein said heavy chain (V_{II}) variable region sequence is at least 95% identical to SEQ ID NO:3.

124. (Previously Presented) The purified polypeptide according to Claim 122, wherein the complementary-determining region (CDR) of said heavy chain (V_{II}) variable region sequence is identical to CDRs [Ser-Tyr-Ala-Met-Ilis (CDR1) and Val-Ile-Ser-Tyr-Asp-Gly-Ser-Asn-Lys-Tyr-Tyr-Ala-Asp-Ser-Val-Lys-Gly (CDR2) and Asp-Arg-Leu-Ala-Val-Ala-Gly-Arg-Pro-Phe-Asp-Tyr (CDR3) SEQ ID NO:3].

125. (Previously Presented) The purified antibody or functional fragment thereof according to Claim 73, wherein said light chain variable region sequence has CDR sequences identical to CDR1, CDR2 and CDR3 of SEQ ID NO:1.

126. (Currently Amended) The purified antibody or functional fragment thereof according to Claim 73, wherein said light chain (V_L) variable region sequence is at least 80% identical to SEQ ID NO:1, or wherein said heavy chain (V_H) variable region sequence is at least [[80%]] 90% identical to SEQ ID NO:3.

127. (Currently Amended) The purified polypeptide according to Claim 122, wherein said heavy chain (V_H) variable region sequence is at least [[80%]] 90% identical to SEQ ID NO:3.

128. (Currently Amended) A purified antibody or functional fragment thereof comprising a light chain (V_L) variable region sequence and a heavy chain (V_H) variable region sequence, wherein said antibody or functional fragment specifically binds to an epitope of an antigen expressed by at least one of BXPC-3 (ATCC Accession No. CRL-1687), 23132/87 (DSMZ Accession No. ACC 201), COLO-206F (DSMZ Accession No. ACC 21), COLO-699 (DSMZ Accession No. ACC 196), or LOU-NH91 (DSMZ Accession No. ACC 393) neoplastic cells and binds to apolipoprotein B containing low density lipoproteins (LDL) and apolipoprotein B containing oxidized LDL (oxLDL), wherein SAM-6 antibody comprising the amino acid

VOLLMERS ET AL. -- 10/579,290
Attorney Docket: 043043-0359295

sequences of SEQ ID NO:1 and SEQ ID NO:3 specifically binds to said epitope of the antigen expressed by at least one of said neoplastic cells, and wherein said light chain (V_L) variable region sequence is at least 90% identical to SEQ ID NO:1, or wherein said heavy chain variable region sequence is at least 90% identical to SEQ ID NO:3.

129. (Previously Presented) The purified antibody or functional fragment thereof according to Claim 127, wherein said light chain (V_L) variable region sequence is at least 95% identical to SEQ ID NO:1, or wherein said heavy chain variable region sequence is at least 95% identical to SEQ ID NO:3.

130. (Previously Presented) The purified antibody or functional fragment thereof according to Claim 127, wherein said light chain (V_L) variable region sequence is at least 90% identical to SEQ ID NO:1, and wherein said heavy chain variable region sequence is at least 90% identical to SEQ ID NO:3.

131. (Currently Amended) A purified polypeptide comprising a heavy chain (V_H) variable region sequence, wherein said heavy chain variable region sequence is at least 90% identical to SEQ ID NO:3, wherein said heavy chain (V_H) variable region sequence specifically binds to an epitope of an antigen expressed by at least one of BXPC-3 (ATCC Accession No. CRL-1687), 23132/87 (DSMZ Accession No. ACC 201), COLO-206F (DSMZ Accession No. ACC 21), COLO-699 (DSMZ Accession No. ACC 196), or LOU-NH91 (DSMZ Accession No. ACC 393) neoplastic cells and binds to apolipoprotein B containing low density lipoproteins (LDL) and apolipoprotein B containing oxidized LDL (oxLDL), and wherein SAM-6 antibody comprising the amino acid sequences of SEQ ID NO:1 and SEQ ID NO:3 specifically binds to said epitope of the antigen expressed by at least one of said neoplastic cells.

132. (Previously Presented) The purified polypeptide according to Claim 131, wherein said heavy chain (V_H) variable region sequence is at least 95% identical to SEQ ID NO:3.